According to the latest figures, there are more than 30 small molecule drugs amassing more than 30 billion dollars annually, with more than 150 in preclinical trials waiting FDA approval (1).

Furthermore, several monoclonal antibodies targeting receptor tyrosine kinases have made tremendous penetration into the cancer immunotherapy market such as Herceptin, Bevacizumab and Cetuximab, etc. The latest figure on the commercial impact of total sales of kinase-related drugs is estimated at .........

You just need to REGISTER - its FREE - to read the rest of this article straight away.